Ali Askari, MD
Cardiovascular Disease · Phoenix, AZNPI 1760554919
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 319 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,073 and has fallen 69.5% since, to $327 in 2025.
Across 319 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$913
- Abbott$736
- Boston Scientific$611
- Novartis$544
- Impulse Dynamics (USA) Inc.$325
- Medtronic$324
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,34997%
- Education$10%
- Entertainment$1563%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 44 | $913 |
| Abbott | 9 | $736 |
| Boston Scientific | 92 | $611 |
| Novartis | 62 | $544 |
| Impulse Dynamics (USA) Inc. | 18 | $325 |
| Medtronic(2 entities) | 7 | $324 |
| AstraZeneca | 15 | $268 |
| Heartflow, Inc. | 2 | $194 |
| Johnson & Johnson | 8 | $193 |
| Kestra Medical Technology Services, Inc. | 7 | $176 |
| Hitachi Healthcare Americas Corp. | 1 | $156 |
| Sanofi-aventis U.S. LLC | 6 | $101 |
| Boehringer Ingelheim | 5 | $101 |
| CMP Pharma, Inc. | 4 | $83 |
| Amarin Pharma, Inc. | 6 | $75 |
| Bardy Diagnostics, Inc. | 5 | $75 |
| Novo Nordisk | 3 | $66 |
| Merck | 3 | $63 |
| Pfizer | 3 | $59 |
| Edwards Lifesciences | 3 | $57 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| Atricure, Inc. | 1 | $46 |
| Lucid Diagnostics Inc. | 1 | $46 |
| Astellas Pharma US Inc | 2 | $42 |
| Sanofi | 1 | $32 |
| Cvrx, Inc. | 1 | $27 |
| Chiesi USA, Inc. | 1 | $27 |
| Philips North America LLC | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $19 |
| Amgen | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| GSK | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$361
- OPTIMIZER$305
- Quadra Assura CRT Defibrillator$241
- Assurity Pacemaker$166
- CardioMEMS HF System$145
- Reveal LINQ$136
- FFRct$135
- Claria MRI$106
How this compares
$5,506 in reported general payments places this provider in the 65th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 323 | $362,547 |
| XareltoRivaroxaban | 204 | $206,617 |
| EntrestoSacubitril/Valsartan | 98 | $103,236 |
| FarxigaDapagliflozin Propanediol | 71 | $85,458 |
| BrilintaTicagrelor | 34 | $26,084 |
| JardianceEmpagliflozin | 15 | $23,857 |
| OzempicSemaglutide | 13 | $11,839 |
| ClopidogrelClopidogrel Bisulfate | 571 | $6,131 |
| Metoprolol Succinate | 420 | $5,725 |
| Losartan Potassium | 382 | $3,426 |
| Atorvastatin Calcium | 446 | $3,321 |
| Amlodipine Besylate | 534 | $3,179 |
| Carvedilol | 398 | $3,079 |
| Potassium Chloride | 141 | $2,824 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 101 | $2,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $59 | $362,547323 claims |
| Johnson & JohnsonXarelto | $193 | $206,617204 claims |
| AstraZenecaFarxiga, Brilinta | $268 | $111,541105 claims |
| NovartisEntresto | $544 | $103,23698 claims |
| Boehringer IngelheimJardiance | $101 | $23,85715 claims |
| Novo NordiskOzempic | $66 | $11,83913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Phoenix
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Tabitha MoePhoenix$182K
- Jesse SethiPhoenix$150K
- Robert ScottPhoenix$106K
- Kethes WaramPhoenix$66K
- Ayman JamalPhoenix$42K
- Sarika DesaiPhoenix$41K
- Suzanne SorofPhoenix$29K
- Namit RohantPhoenix$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.